Lorqess' Slight Efficacy, Potential Safety Issues Leave Arena On The Hot Seat At Advisory Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA seeks input on the "slim margin" of efficacy and the adequacy of safety data for Arena's obesity drug.
You may also be interested in...
What Belviq Labeling Means For Other Obesity Drug Sponsors
Arena’s Belviq is the first obesity drug approval in over a decade, but it won’t be the only one for long. A look at the FDA-approved labeling for lorcaserin offers a preview of how the agency could handle similar issues for Qnexa and, further down the line, Contrave.
Positive Panel Recommendation For Contrave Could Change Obesity Drug Game
FDA's Endocrinologic and Metabolic Drugs Advisory Committee's surprise vote recommending Orexigen Therapeutics’ obesity drug Contrave (naltrexone SR/bupropion SR) for approval has boosted hopes that at least some of the current generation of obesity drugs in development may reach the market – just not in the order that everyone had expected.
Positive Panel Recommendation For Contrave Could Change Obesity Drug Game
FDA's Endocrinologic and Metabolic Drugs Advisory Committee's surprise vote recommending Orexigen Therapeutics’ obesity drug Contrave (naltrexone SR/bupropion SR) for approval has boosted hopes that at least some of the current generation of obesity drugs in development may reach the market – just not in the order that everyone had expected.